Vendor Intelligence Report: Aminos Research

Published 3 Jul 2026. 25-page investigative report on who is behind Aminos Research: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Aminos Research is a legacy-vendor diligence problem, not a simple vendor scorecard. Across 4 Finnrick lab tests, the overall pass rate is 75%: 3 pass and 1 fail. The tiny record splits by product: GHK-Cu is the stronger historical signal, while semaglutide is the weak point and should be compared with active vendors that have cleaner current semaglutide histories. Tighter grading makes the two-product record more fragile than the headline suggests.

The larger buyer issue is channel authenticity. The canonical domain is suspended under clientHold and parked; archived shop evidence points to hiatus or empty-store conditions; and no official 2026 storefront or ownership-transfer notice was found. A Reddit account claimed the brand was back under new ownership, but the report treats that as an unverified social artifact, not a purchase channel.

The historical identity trail is stronger: South Carolina and BBB records, archived addresses, WHOIS fields, and personnel artifacts identify the former operation and Brandon Seth’s later pivot into Aminos Analytics. The report separates that lab-service continuity from revived-retail claims, and treats Profound Aminos as similar-name confusion unless better evidence appears.

The highest-severity historical issue is a 2024 forum-documented attempt to promote a purported novel GLP-1/GIP analog. The original Facebook post was not located, so the report grades the incident carefully; still, the forum warning and referral ban show an operator-judgment risk that ordinary purity testing cannot resolve.

Inside the full report:

  • Complete Finnrick pass/fail breakdown, rating trajectories, and methodology-divergence charts for both tested products
  • WHOIS and Wayback exhibits covering the suspended domain, residual captures, and missing current shop evidence
  • South Carolina, BBB, archived-address, and personnel-control evidence for the former Aminos Research operation
  • Evidence timeline for the 2024 novel GLP-1/GIP analog controversy and reported halt
  • Assessment of 2026 new-ownership Reddit claims, Aminos Analytics continuity, Profound Aminos rumors, coupon pages, and promotion-network dead ends

Risk assessment

  • Post-closure authenticity and brand-confusion risk — high: aminos-research.com is suspended with no verified official purchase channel; April 2026 new-ownership claims and coupon pages lack authoritative corroboration.
  • Untested novel-compound commercialization risk — high: September 2024 forum records describe promotion of a purported novel GLP-1/GIP analog without located published safety data, peer review, rodent testing, or FDA filings.
  • Semaglutide quality reliability risk — high: Semaglutide specifically has 2 Finnrick tests with 1 pass and 1 fail and a 65.79% rating.
  • Alleged community-platform conflict-of-interest risk — medium: GLP-1 Forum users alleged Peppys funding/control and criticism suppression involving Brandon Seth; the allegation is unverified but material to community-signal reliance.